PMID- 36832327
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230228
IS  - 2227-9067 (Print)
IS  - 2227-9067 (Electronic)
IS  - 2227-9067 (Linking)
VI  - 10
IP  - 2
DP  - 2023 Jan 20
TI  - Home Immunization with Palivizumab-A Randomized Pilot Study Describing Safety 
      Aspects and Parents' Preferences.
LID - 10.3390/children10020198 [doi]
LID - 198
AB  - Among prematurely born infants and newborns with chronic conditions, a 
      respiratory syncytial virus (RSV) infection may cause (re-)admission and later 
      respiratory complications. Therapeutic protection is possible with monthly 
      injections of a specific monoclonal antibody, palivizumab, during RSV season. 
      Standard care is giving up to five injections in clinic-based settings. 
      Immunization at home could be an alternative to standard care for vulnerable 
      infants to reduce the number of revisits and associated risk of RSV infection. 
      The aim of this randomized pilot trial was to evaluate safety aspects and explore 
      parents' preferences of home versus hospital immunization with palivizumab during 
      one RSV season. Immediate adverse events (AEs) were observed and registered by a 
      pediatric specialist nurse. Late-onset AEs were reported by parents. Parents' 
      perceptions were collected through a questionnaire and analyzed using content 
      analysis. The study population consisted of 43 infants in 38 families. No 
      immediate AEs occurred. Three late-onset AEs were reported in two infants in the 
      intervention group. Three categories emerged in the content analysis: (1) protect 
      and watch over the infant, (2) optimal health and well-being for the whole 
      family, and (3) avoid suffering for the infant. The study results show that home 
      immunization with palivizumab is feasible if safety aspects are considered and 
      that parental involvement in the choice of place for immunization after a 
      neonatal intensive care experience can be important.
FAU - Ebersjo, Christina
AU  - Ebersjo C
AUID- ORCID: 0000-0002-7578-8555
AD  - Department of Clinical Science and Education, Sodersjukhuset, Karolinska 
      Institute, 171 77 Stockholm, Sweden.
AD  - Sach's Children and Youth Hospital, Sodersjukhuset AB, 118 83 Stockholm, Sweden.
FAU - Berggren Brostrom, Eva
AU  - Berggren Brostrom E
AD  - Department of Clinical Science and Education, Sodersjukhuset, Karolinska 
      Institute, 171 77 Stockholm, Sweden.
FAU - Kull, Inger
AU  - Kull I
AD  - Department of Clinical Science and Education, Sodersjukhuset, Karolinska 
      Institute, 171 77 Stockholm, Sweden.
AD  - Sach's Children and Youth Hospital, Sodersjukhuset AB, 118 83 Stockholm, Sweden.
FAU - Lindholm Olinder, Anna
AU  - Lindholm Olinder A
AUID- ORCID: 0000-0002-8422-2457
AD  - Department of Clinical Science and Education, Sodersjukhuset, Karolinska 
      Institute, 171 77 Stockholm, Sweden.
AD  - Sach's Children and Youth Hospital, Sodersjukhuset AB, 118 83 Stockholm, Sweden.
LA  - eng
GR  - 556046-6137/Abbvie (Scandinavia)/
PT  - Journal Article
DEP - 20230120
PL  - Switzerland
TA  - Children (Basel)
JT  - Children (Basel, Switzerland)
JID - 101648936
PMC - PMC9955059
OTO - NOTNLM
OT  - content analysis
OT  - home immunization
OT  - palivizumab
OT  - parents' preferences
OT  - randomized controlled
OT  - safety
COIS- The authors declare no conflict of interest.
EDAT- 2023/02/26 06:00
MHDA- 2023/02/26 06:01
PMCR- 2023/01/20
CRDT- 2023/02/25 01:52
PHST- 2022/11/10 00:00 [received]
PHST- 2023/01/16 00:00 [revised]
PHST- 2023/01/18 00:00 [accepted]
PHST- 2023/02/25 01:52 [entrez]
PHST- 2023/02/26 06:00 [pubmed]
PHST- 2023/02/26 06:01 [medline]
PHST- 2023/01/20 00:00 [pmc-release]
AID - children10020198 [pii]
AID - children-10-00198 [pii]
AID - 10.3390/children10020198 [doi]
PST - epublish
SO  - Children (Basel). 2023 Jan 20;10(2):198. doi: 10.3390/children10020198.